173 related articles for article (PubMed ID: 7698709)
1. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.
Laurent-Puig P; Lubin R; Semhoun-Ducloux S; Pelletier G; Fourre C; Ducreux M; Briantais MJ; Buffet C; Soussi T
Gut; 1995 Mar; 36(3):455-8. PubMed ID: 7698709
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M; Sudo H; Kawauchi J; Takizawa S; Kondou S; Nobumasa H; Ochiai A
PLoS One; 2015; 10(2):e0118220. PubMed ID: 25706130
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
5. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma.
Raedle J; Oremek G; Welker M; Roth WK; Caspary WF; Zeuzem S
Pancreas; 1996 Oct; 13(3):241-6. PubMed ID: 8884844
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
[TBL] [Abstract][Full Text] [Related]
7. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.
Marxsen J; Schmiegel W; Röder C; Harder R; Juhl H; Henne-Bruns D; Kremer B; Kalthoff H
Br J Cancer; 1994 Nov; 70(5):1031-4. PubMed ID: 7947080
[TBL] [Abstract][Full Text] [Related]
8. P53 levels in the evaluation of malignant/benign pancreaticobiliary disease: hope or hype?
Gessner CE; Baillie J
Am J Gastroenterol; 1996 Feb; 91(2):401-2. PubMed ID: 8607524
[No Abstract] [Full Text] [Related]
9. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas.
Nanashima A; Yamaguchi H; Nakagoe T; Matsuo S; Sumida Y; Tsuji T; Sawai T; Yamaguchi E; Yasutake T; Ayabe H
J Hepatobiliary Pancreat Surg; 1999; 6(4):391-5. PubMed ID: 10664288
[TBL] [Abstract][Full Text] [Related]
10. Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer.
Hedström J; Haglund C; Kemppainen E; Leinimaa M; Leinonen J; Stenman UH
Clin Chem; 1999 Oct; 45(10):1768-73. PubMed ID: 10508123
[TBL] [Abstract][Full Text] [Related]
11. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
12. Identification of carcinoembryonic antigen (CEA) in bile of patients with malignant biliary tract disease.
Konomi K; Nakamura K; Tobimatsu M; Saito S; Toyoda K; Yasunami Y
Jpn J Surg; 1982; 12(3):184-90. PubMed ID: 7131963
[TBL] [Abstract][Full Text] [Related]
13. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
14. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
Yamaguchi K; Nakano K; Nagai E; Chijiiwa K; Kinoshita M; Ohta M; Tanaka M
Hepatogastroenterology; 2005; 52(63):713-8. PubMed ID: 15966189
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
16. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients.
Cressey R; Pimpa S; Chewaskulyong B; Lertprasertsuke N; Saeteng S; Tayapiwatana C; Kasinrerk W
BMC Biotechnol; 2008 Feb; 8():16. PubMed ID: 18284706
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
18. [Effect of biliary obstruction and cholangitis on serum SPan-1 level].
Matsumoto S; Muranaka T; Hanada K; Matsuura Y; Oshiumi Y
Kaku Igaku; 1990 Dec; 27(12):1443-6. PubMed ID: 2290216
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.
Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M
Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945
[TBL] [Abstract][Full Text] [Related]
20. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.
Li J; Wang LJ; Ying X; Han SX; Bai E; Zhang Y; Zhu Q
Scand J Immunol; 2012 Mar; 75(3):342-9. PubMed ID: 22010875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
